Avicidin therapy where antibody is injected before the radionuclide yttrium-90 to pretarget tumor data

NERX (Seattle) announced Phase I/II data on its Avicidin therapy at the Mabon Securities conference in New York, reporting that tumor-to-blood ratios were improved 10-fold compared to conventional rad...